SANTA MONICA, Calif., March 25, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products based on chimeric antigen receptor (CAR) and T cell receptor (TCR) gene therapy for the treatment of cancer, today announced that it will issue a press release with its financial results and company highlights for the fourth quarter and year ended December 31, 2014, on Thursday, March 26, 2015.
About Kite Pharma
Kite Pharma, Inc., is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a primary focus on eACT™ designed to restore the immune system's ability to recognize and eradicate tumors. Kite is based in Santa Monica, CA. For more information on Kite Pharma, please visit www.kitepharma.com.
CONTACT: Kite Pharma Cynthia M. Butitta Chief Financial Officer and Chief Operating Officer 310-824-9999 For Media: Justin Jackson For Investor Inquiries: Lisa Burns and Nancy Yu Burns McClellan 212-213-0006 email@example.com firstname.lastname@example.org email@example.com
Source:Kite Pharma, Inc.